Peptide News Digest

GLP-1s in Older Adults Without Diabetes, Fewer Clots After Knee Replacement, Tirzepatide and Hidden Type 1 Diabetes

Sustained GLP-1 use tracks with better BMI in 13,387 older Israelis, fewer clots after knee surgery, and a tirzepatide user turns out to have type 1 diabetes.

8 stories · Covering research

Editor's Note

Thursday's research was mostly about how GLP-1 drugs behave outside the trials that got them approved. An Israeli study of 13,387 adults over 65 without diabetes found that people who kept filling prescriptions improved their BMI and blood sugar far more often than those who stopped after one or two fills, and a U.S. records study linked GLP-1 use before knee replacement to fewer heart attacks and blood clots afterward; both are observational and cannot rule out healthier patients staying on the drugs. A Wuhan case report described a 28-year-old who lost 15 kg on tirzepatide he took without medical supervision and was then diagnosed with autoimmune type 1 diabetes in ketoacidosis, a reminder that weight loss can mask a different disease. Two reviews looked at what the big trials measured: a meta-analysis found lean-mass loss on semaglutide and tirzepatide with wide uncertainty, and an Istanbul team argued that the trials never measured nausea with a validated patient questionnaire. Lab papers rounded out the day with a brain-targeted peptide for Parkinson's disease, a machine-learning-picked antifungal peptide, and a peptide-coated scaffold implanted in pig spinal cords.

Research

Israeli Older Adults Without Diabetes Who Kept Filling GLP-1 Prescriptions Improved Their BMI Category Nearly Twice as Often as Those Who Stopped Early

A Clalit Health Services study published October 22, 2026 in Diabetes, Obesity and Metabolism followed 13,387 Israelis aged 65 and older with a BMI of 30 or higher and no diabetes who started a GLP-1 drug, comparing 11,121 with sustained use (three or more dispensations) against 2,266 with one or two. BMI category improved in 55% versus 30% (median BMI change of -8% versus -2%; adjusted odds ratio 2.77), HbA1c category improved in 34% versus 20% of the 7,392 with paired tests, and 65% versus 37% of those with prediabetes returned to normal blood sugar. New diabetes diagnoses were 2.5% versus 5.3%; the authors note the retrospective design describes changes after starting treatment and does not prove causation.

#glp-1 #real-world-evidence #type-2-diabetes #obesity
Research

GLP-1 Use Before Knee Replacement Linked to About Half the Rate of Postoperative Heart Attacks and Fewer Blood Clots in a TriNetX Study

Researchers at the University of Arizona College of Medicine-Phoenix reported in The Journal of Knee Surgery on October 22, 2026 a TriNetX study of adults having a first total knee replacement, matching 11,765 who had a GLP-1 prescription in the year before surgery with 11,765 who did not. GLP-1 users had fewer heart attacks (25 vs 47 events; risk ratio 0.53), deep vein thromboses (74 vs 103; 0.72), and venous thromboembolisms (133 vs 172; 0.77), while pulmonary embolism rates did not differ significantly. The study is observational and based on prescription records.

#glp-1 #orthopedics #cardiovascular #real-world-evidence
Research

Wuhan Doctors Report Autoimmune Type 1 Diabetes With Ketoacidosis in a 28-Year-Old Who Lost 15 kg on Unsupervised Tirzepatide

Endocrinologists at Zhongnan Hospital of Wuhan University described in Frontiers in Endocrinology on October 22, 2026 a 28-year-old man with obesity and no known high blood sugar who injected tirzepatide on his own, lost 15 kg over about three months, and was then diagnosed with GADA antibody-positive type 1 diabetes presenting as diabetic ketoacidosis, with an HbA1c of 10.8% and GADA above 2,000 IU/mL. On insulin, his HbA1c fell to 6.7% at three months. The authors say a single case cannot show that tirzepatide or stopping it caused the diabetes, and that the high HbA1c suggests high blood sugar came first; their message is to consider autoimmune diabetes when unexplained hyperglycemia, continued weight loss, or ketoacidosis appears during self-directed weight-loss treatment.

#tirzepatide #type-1-diabetes #case-report #side-effects
Research

Meta-Analysis of Five Phase 3 Trials Finds Lean Mass About 3.4 to 4.4 kg Lower on Semaglutide 2.4 mg and Tirzepatide Than Placebo, With Wide Uncertainty

A meta-analysis published October 21, 2026 in BMC Endocrine Disorders pooled DXA body-composition data from five Phase 3 trials with 569 adults. In the two placebo-controlled obesity trials (semaglutide 2.4 mg and tirzepatide, 68 to 72 weeks), lean body mass was 3.43 and 4.40 kg lower and fat mass 6.99 and 12.30 kg lower than with placebo, but the pooled lean-mass estimate (-3.95 kg) had a 95% confidence interval crossing zero. Across all five trials, lean mass was 2.49 kg lower, a result that lost statistical significance when any one of three trials was dropped; DXA lean mass also includes water and organ tissue, not just muscle.

#semaglutide #tirzepatide #body-composition #lean-mass
Research

Review: The STEP, SURMOUNT, and SCALE Obesity Trials Recorded Nausea Only as Spontaneously Reported Adverse Events, Not With a Validated Patient Questionnaire

Researchers at Istanbul Medipol University argued in a narrative review in Diabetes, Obesity and Metabolism, published October 22, 2026, that the major liraglutide (SCALE), semaglutide (STEP), and tirzepatide (SURMOUNT) obesity programs captured nausea through investigator-recorded adverse events coded in MedDRA rather than any validated, symptom-specific patient-reported tool, while the same programs used detailed quality-of-life questionnaires. They suggest this gap may help explain why real-world persistence on GLP-1 drugs falls short of what trial tolerability figures predict, and they outline what a dedicated nausea measure would need to capture. The paper is an argument based on published methods, not new data.

#glp-1 #side-effects #semaglutide #tirzepatide
Research

China Pharmaceutical University's 'Zipper' Peptide Blocks VHL in Dopamine Neurons and Eases Motor Deficits in Two Animal Models of Parkinson's

Researchers at China Pharmaceutical University reported in Advanced Functional Materials on October 22, 2026 a leucine zipper-inspired peptide that binds the protein VHL, packed into a lipid nanocomplex carrying the T7 targeting peptide so that it reaches dopamine-producing neurons and their mitochondria. Given systemically, the complex reached those neurons within two hours, released the peptide in acidic conditions, and disrupted VHL's interaction with DVL-2, raising β-catenin and hexokinase 2 and improving mitochondrial energy production. Treatment reduced neurodegeneration and motor and coordination deficits in both an MPTP toxin model and an α-synuclein overexpression model; the work is preclinical.

#parkinsons #neuroprotection #drug-delivery #preclinical
Research

Machine Learning Picks a Heat-Stable Cationic Peptide, P2, That Inhibits Candida albicans and C. parapsilosis in Lab Tests

Researchers at Mexico's Ensenada Center for Scientific Research and Higher Education (CICESE) reported in the Journal of Applied Microbiology on October 22, 2026 that of four machine-learning-selected peptides, one called P2 had the best activity profile. It inhibited two Candida albicans reference strains and a C. parapsilosis clinical isolate at 62.5 µM, while C. glabrata needed 250 µM, and it still killed bacteria after 15 minutes at 100°C. Hemolysis reached 12% at 500 µM, and human 293T cells were unaffected up to 50 µM but badly damaged at 500 µM; the work is in lab cultures only.

#antimicrobial-peptides #antifungal #candida #machine-learning
Research

Kazan Team's Peptide-Coated Cryogel Scaffold, Including GHK and RGD, Integrates Into Pig Spinal Cords in a Pilot Bridging Study

Researchers at Kazan Federal University in Russia reported in Macromolecular Bioscience on October 21, 2026 a macroporous, multi-channel hydrogel scaffold made from oligo(poly(ethylene glycol) fumarate) and coated with four signaling peptides, IKVAV, RGD, GHK, and LRE, intended to bridge a completely severed spinal cord without added cells or growth factors. The peptide mix promoted nerve-cell growth in culture, and in a pilot study in minipigs with a cut spinal cord the implant integrated with tissue, kept its structure, and was infiltrated by host cells. The pilot looked at short-term integration, not recovery of movement.

#spinal-cord-injury #peptide-hydrogel #regenerative-medicine #preclinical

Related Guides